Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 11, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odyssey Therapeutics, Inc.
Report date May 11, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,333,516 |
Last balance in matching sequence
After 2026-05-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-05-11 · Conversion · Acquired 1,709,543 · Balance 2,222,405 F1: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F2: These securities are held by Dimension Capital II, L.P. Dimension Capital II, L.P. is controlled by Dimension Capital II GP, L.P., its general partner, which is itself controlled by Dimension Capital II GP, LLC. The Reporting Person, Adam Goulburn and Zavain Dar serve as the members of Dimension Capital II GP, LLC. The Reporting Person disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Row 2 · 2026-05-11 · Purchase · Acquired 1,111,111 · Balance 3,333,516 F3: Reflects shares purchased in the Issuer's initial public offering. F2: These securities are held by Dimension Capital II, L.P. Dimension Capital II, L.P. is controlled by Dimension Capital II GP, L.P., its general partner, which is itself controlled by Dimension Capital II GP, LLC. The Reporting Person, Adam Goulburn and Zavain Dar serve as the members of Dimension Capital II GP, LLC. The Reporting Person disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-11 · Conversion · Disposed 16,611,626 · Balance 0 F1: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F2: These securities are held by Dimension Capital II, L.P. Dimension Capital II, L.P. is controlled by Dimension Capital II GP, L.P., its general partner, which is itself controlled by Dimension Capital II GP, LLC. The Reporting Person, Adam Goulburn and Zavain Dar serve as the members of Dimension Capital II GP, LLC. The Reporting Person disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F2: These securities are held by Dimension Capital II, L.P. Dimension Capital II, L.P. is controlled by Dimension Capital II GP, L.P., its general partner, which is itself controlled by Dimension Capital II GP, LLC. The Reporting Person, Adam Goulburn and Zavain Dar serve as the members of Dimension Capital II GP, LLC. The Reporting Person disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.
F3: Reflects shares purchased in the Issuer's initial public offering.
F4: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2026 Filed May 12, 2026 00:30 UTC | Odyssey Therapeutics, Inc. ODTX · Entity 4850 | ConversionSeries D Convertible Preferred Stock · Derivative | 16,611,626 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-217593 · ownership.xml · derivative · entry 3 Li Nan (LN) · CIK 0002131608 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,709,543 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F1 · price: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F1 · derivative.exercise_date: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F1 · derivative.expiration_date: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4 · derivative.underlying_shares: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: These securities are held by Dimension Capital II, L.P. Dimension Capital II, L.P. is controlled by Dimension Capital II GP, L.P., its general partner, which is itself controlled by Dimension Capital II GP, LLC. The Reporting Person, Adam Goulburn and Zavain Dar serve as the members of Dimension Capital II GP, LLC. The Reporting Person disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Read SEC document |
| May 11, 2026 Filed May 12, 2026 00:30 UTC | Odyssey Therapeutics, Inc. ODTX · Entity 4850 | PurchaseCommon Stock | 1,111,111 | $18.00 | $19,999,998.00 |
DisclosureSEC source: 0001193125-26-217593 · ownership.xml · nonDerivative · entry 2 Li Nan (LN) · CIK 0002131608 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,333,516 F3 · shares: Reflects shares purchased in the Issuer's initial public offering. F2 · ownership.nature: These securities are held by Dimension Capital II, L.P. Dimension Capital II, L.P. is controlled by Dimension Capital II GP, L.P., its general partner, which is itself controlled by Dimension Capital II GP, LLC. The Reporting Person, Adam Goulburn and Zavain Dar serve as the members of Dimension Capital II GP, LLC. The Reporting Person disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Read SEC document |
| May 11, 2026 Filed May 12, 2026 00:30 UTC | Odyssey Therapeutics, Inc. ODTX · Entity 4850 | ConversionCommon Stock | 1,709,543 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-217593 · ownership.xml · nonDerivative · entry 1 Li Nan (LN) · CIK 0002131608 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,222,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F2 · ownership.nature: These securities are held by Dimension Capital II, L.P. Dimension Capital II, L.P. is controlled by Dimension Capital II GP, L.P., its general partner, which is itself controlled by Dimension Capital II GP, LLC. The Reporting Person, Adam Goulburn and Zavain Dar serve as the members of Dimension Capital II GP, LLC. The Reporting Person disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.